Prosetin - ProJenX
Latest Information Update: 01 Apr 2024
At a glance
- Originator Columbia University; Project A.L.S.
- Developer ProJenX
- Class Neuroprotectants; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
Most Recent Events
- 28 Mar 2024 US FDA removed a partial clinical hold on phase I study PRO-101 for Amyotrophic lateral sclerosis
- 14 Feb 2024 ProJenX receives European authorization for clinical trial of prosetin in Amyotrophic lateral sclerosis (ALS)
- 29 Nov 2023 ProJenX receives authorization of clinical trial application from Health Canada for Prosetin for amyotrophic lateral sclerosis (ALS)